摘要
68例新接受肾移植的患者应用新山地明胶囊，其用量比山地明减少16.64％，全血浓度谷值维持稳定[3个月平均值（318．46±7826）μg／L]，仅1例发生急性排斥反应，4例发生肝毒性，3例发生肾毒性。18例由山地明或国产环孢素转换为新山地明的患者，免疫抑制效果满意，无排斥反应和明显的药物毒副作用，仅1例开始转换后出现过血肌研值升高。说明新山地明的生物利用度高，药物代谢动力学稳定，临床应用免疫抑制效果比山地明好。
68 patients newly receiving renaltransplantation were treated with Sandimmun Neoral. The dosage of Sandimmun Neoral decreased16. 64% compared with Sandimmun, and the blood trough level was stable. The average blood trough level of Sandimmun Neoral was (318. 46 ±78. 26) μg/L within 3 months. One, four and three patients suffered from the acute rejection, hepatitis and nephrotoxicity, respectively. 18 patients transferred from Sandimmun to Sandimmun Neoral, the satisfying effect was achieved. There were no rejection or obvious toxic and side effects at the very beginning of using Sandimrnun Neoral. All the above indicate that Sandimmun Neoral has high bioavailability,stable blood trough level, and satisfactory immunosuppressive effect in clinic. Compared with the old Sandimmun, Sandimmun Neoral is more safe and more effective.
出处
《西安医科大学学报》
CSCD
1997年第4期513-515,共3页
Journal of Xi'an Medical University(Chinese)
